- Home
- GCDT vs CANF Comparison
GCDT vs CANF Comparison
Compare GCDT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | CANF |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 6.0M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GCDT | CANF |
|---|---|---|
| Price | $0.61 | $3.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 323.6K | ★ 1.8M |
| Earning Date | 05-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.17 |
| 52 Week High | $5.32 | $10.40 |
Technical Indicators
Market Signals| Indicator | GCDT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 51.18 |
| Support Level | $0.55 | $2.88 |
| Resistance Level | $1.47 | $3.42 |
| Average True Range (ATR) | 0.06 | 0.51 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 47.95 | 22.81 |
Price Performance
Historical ComparisonAbout GCDT Green Circle Decarbonize Technology Limited Ordinary Shares
Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.